The Alzheimer’s Drug Discovery Foundation (ADDF) supports the most promising and diverse research projects around the world in an effort to identify new drugs for Alzheimer’s and related dementias. Our grantees are focused on early-stage research, from drug target validation through early-phase clinical trials. To date, the ADDF has invested more than $66 million to support over 450 Alzheimer’s drug discovery programs in 18 countries.
The ADDF is exclusively focused on translating the knowledge we have gained about the underlying causes of Alzheimer’s disease into drugs. We fund programs in both academia and biotechnology companies worldwide, with priority funding in drug discovery and preclinical drug development, early detection, clinical trials and prevention.
The ADDF facilitates critical knowledge sharing and idea exchanges by actively convening and sponsoring scientific conferences around the globe. We also organize advisory panels focused on key issues surrounding drug discovery and development for Alzheimer’s.
Drug discovery is a team effort, requiring collaboration between scientists with many different types of experience, from biology to chemistry to pharmacology. To help scientists access the expertise they need, the ADDF established the ADDF ACCESS program. In addition to connecting scientists with networks of collaborators, consultants, contract research organizations (CROs) and experimental tools, the program provides Alzheimer’s scientists with educational materials on the drug discovery process, and guidance and expertise on the process of selecting and managing CRO relationships.
To learn more about the ADDF ACCESS program, please contact Lauren Friedman, PhD, program manager of scientific affairs, at (212) 901-8017.
The ADDF’s Aging and Alzheimer’s Prevention program works to evaluate, communicate and accelerate the science of Alzheimer’s and cognitive-aging prevention therapies. Our scientists have assessed the scientific evidence for and against over 100 suggested therapies to prevent brain aging or dementia, and written a number of peer-reviewed scientific articles about potential prevention strategies. Through the program, the ADDF also organizes advisory panels to expedite prevention therapy development and funds high-risk catalytic research.
To learn more about aging and Alzheimer’s prevention, visit the Aging and Alzheimer’s Prevention program's site, Cognitive Vitality.